logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
PE/iFluor® 594 Anti-human CD150 Antibody
SLAM.4
The SLAM.4 monoclonal antibody binds with human CD150, a 70 - 95 kD glycoprotein commonly located on the surface of B cells, dendritic cells, endothelial cells, T cells and Tregs. CD150 plays a role in important cellular pathways, in particular, the negative regulation of CD40 signaling pathway. In addition, in certain organisms, it is a negative regulator of tumor necrosis factor production, suppresses interleukin-6 production and plays a role in the upregulation of JNK cascade. From a research standpoint, it is of biological interest due to its association with critical macromolecules/ligands such as tyrosine phosphatase CD45. CD150 is a fairly uncommon antibody target, with a little more than 2700 publications in the last decade. Even still, CD150 is often used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology. This antibody was purified through affinity chromatography and conjugated to PE/iFluor® 594 (ex/em = 566/606 nm). It is compatible with the 561 nm laser and 610/20 nm bandpass filter (for example, as in the BD LSRFortessa™ X-20).
product image
product image
CatalogSize
Price
Quantity
115001Y025 tests
Price
115001Y1100 tests
Price
115001Y2500 tests
Price
 
Antibody properties

Other namesSLAM; IPO-3
CloneSLAM.4
Hostmouse
IsotypeMouse IgG1
Reactivityhuman
Spectral properties

Absorbance (nm)566
Extinction coefficient (cm -1 M -1)
1960000
Excitation (nm)565
Emission (nm)606
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on October 4, 2025